SG11201900464TA - HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) - Google Patents

HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)

Info

Publication number
SG11201900464TA
SG11201900464TA SG11201900464TA SG11201900464TA SG11201900464TA SG 11201900464T A SG11201900464T A SG 11201900464TA SG 11201900464T A SG11201900464T A SG 11201900464TA SG 11201900464T A SG11201900464T A SG 11201900464TA SG 11201900464T A SG11201900464T A SG 11201900464TA
Authority
SG
Singapore
Prior art keywords
seq
international
dyygssawitywgqgtlvtvss
pct
rule
Prior art date
Application number
SG11201900464TA
Inventor
Kevin Peters
Michael Allen Flynn
Original Assignee
Aerpio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerpio Therapeutics Inc filed Critical Aerpio Therapeutics Inc
Publication of SG11201900464TA publication Critical patent/SG11201900464TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property C.--.` Organization 1 MEM 0 11101 HOE HI 1 0 0111111010 HO HE 010 HAIM 011 International Bureau (10) International Publication Number (43) International Publication Date .../- WO 2018/017714 Al 25 January 2018 (25.01.2018) WIP0 I PCT (51) International Patent Classification: (74) Agent: OH, Young In et al.; Wilson Sonsini Goodrich & A61K 38/02 (2006.01) C07K 16/28 (2006.01) Rosati, 650 Page Mill Road, Palo Alto, California 94304 A61K 39/395 (2006.01) C07K 16/32 (2006.01) (US). A61K 51/10 (2006.01) C12N 9/96 (2006.01) C07K 16/46 (2006.01) C12N 15/13 (2006.01) (81) Designated States (unless otherwise indicated, for every CO7K 16/24 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, PCT/US2017/042855 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 19 July 2017 (19.07.2017) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/364,381 20 July 2016 (20.07.2016) US kind of regional protection available): ARIPO (BW, GH, 62/377,072 19 August 2016 (19.08.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (71) Applicant: AERPIO THERAPEUTICS, INC. [US/US]; UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 9987 Carver Road, Suite 420, Cincinnati, Ohio 45242 (US). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (72) Inventors: PETERS, Kevin; 9160 Given Road, Cincinnati, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = Ohio 95243 (US). FLYNN, Michael Allen; 3890 High- TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, lander Way West, Ann Arbor, Michigan 48108 (US). KM, ML, MR, NE, SN, TD, TG). Title: HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (54) (HPTP-B) = = 1 5D = - (SEQ ID NO: 50) VHO EVQLVETGGGLVQPKGSMKLSCAASGFTFNANAMNWIRQAPGKGLEWVAR - (SEQ ID NO: 9) VH1 EVQLVESGGGLVQPGGSLKLSCAASGFTFNANAMNWVRQASGKGLEWVGR (SEQ ID NO: 10) VH2 EVQLVESGGGLVQPGGSLRLSCAASGFTFNANAMNWVRQAPGKGLEWVGR = (SEQ ID NO: 11) VH3 EVQLVESGGGLVQPGRSLRLSCTASGFTFNANAMNWVRQAPGKGLEWVGR (SEQ ID NO: 12) VH4 LVQLVESGGGLVKPGGSLRLSCAASGFTFNANAMNWIRQAPGKGLEWVSR = 51 100 = - (SEQ ID NO: 50) VE0 IRTKSNNYATYYAGSVKDRFTIORDDAQNMLYLOMNDLKTEDTAMYYOVR _ (SEQ ID NO: 9) VH1 IRTKSNNYATYYAGSVKDRFTIORDOSKNTAYLOMNSIKTEDTAAYYCVR = (SEQ ID NO: 10) VH2 IRTKSNNYATYYAGSVKDRFTISRDOSKNSLYLQMNSINTEDTAVYYCVR = (SEQ ID NO: 11) VH3 IRTKSNNYATYYAGSVKDRFTISRDOSKNIAYLQMNSINTEDTAVYYCVR = (SEQ ID NO: 12) VH4 IRTKSNNYATYYAGSVKDRFTISRONAKNSLYLQMNSLRAEDTAVHYCVR = 101 122 - (SEQ ID NO: 50) VHO DYYGSSAWITYWGQGTLVTVSA = (SEQ ID NO: 9) VHI DYYGSSAWITYWGQGTLVTVSS (SEQ ID NO: 10) VH2 DYYGSSAWITYWGQGTLVTVSS (SEQ ID NO: 11) VH3 DYYGSSAWITYWGQGTLVTVSS - (SEQ ID NO: 12) VH4 DYYGSSAWITYWGQGTLVTVSS 11 FIGURE 1 1 1' 11 IN IN 11 © --.... GC 11 N (57) : The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis _ comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject. [Continued on next page] WO 2018/017714 Al MIDEDIMOMMIDIREIENIRMEMOIDHEMOVOIS Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event amendments (Rule 48.2(h)) of receipt of
SG11201900464TA 2016-07-20 2017-07-19 HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) SG11201900464TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364381P 2016-07-20 2016-07-20
US201662377072P 2016-08-19 2016-08-19
PCT/US2017/042855 WO2018017714A1 (en) 2016-07-20 2017-07-19 HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)

Publications (1)

Publication Number Publication Date
SG11201900464TA true SG11201900464TA (en) 2019-02-27

Family

ID=60988231

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201900464TA SG11201900464TA (en) 2016-07-20 2017-07-19 HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
SG10201912556VA SG10201912556VA (en) 2016-07-20 2017-07-19 HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912556VA SG10201912556VA (en) 2016-07-20 2017-07-19 HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)

Country Status (13)

Country Link
US (6) US10253094B2 (en)
EP (1) EP3487518A4 (en)
JP (3) JP7107914B2 (en)
KR (1) KR20190031246A (en)
CN (1) CN109715189A (en)
AU (2) AU2017299581B2 (en)
BR (1) BR112019001206A2 (en)
CA (1) CA3030298A1 (en)
IL (1) IL263936A (en)
MX (1) MX2019000727A (en)
PH (1) PH12019500145A1 (en)
SG (2) SG11201900464TA (en)
WO (1) WO2018017714A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ571300A (en) 2006-04-07 2011-12-22 Warner Chilcott Co Llc Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
ES2774972T3 (en) * 2011-10-13 2020-07-23 Aerpio Therapeutics Inc Treatment of eye diseases
CN104039351A (en) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 Methods for treating vascular leak syndrome and cancer
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US10253094B2 (en) 2016-07-20 2019-04-09 Aerpio Therapeutics, Inc. Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
CA3121573A1 (en) * 2018-12-03 2020-06-11 Agensys, Inc. Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
EP3959216A4 (en) * 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
GB2589400A (en) 2019-06-24 2021-06-02 Aerpio Pharmaceuticals Inc Formulations of tie-2 activators and methods of use thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500078A (en) 1997-04-07 2001-10-26 Genentech Inc Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
DE60003011T2 (en) 1999-03-26 2004-04-08 Regeneron Pharmaceuticals, Inc. MODULATING VASCER PERMABILITY BY TIE2 RECEPTOR ACTIVATORS
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
US20020068066A1 (en) * 1999-08-20 2002-06-06 Wenyuan Shi Method for the treatment and prevention of dental caries
IL152794A0 (en) 2000-06-23 2003-06-24 Schering Ag Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use
EP1437143A4 (en) 2001-09-28 2007-05-09 Santen Pharmaceutical Co Ltd Injections for eye tissue containing drug bound to polyethylene glycol
US20050260132A1 (en) 2001-10-17 2005-11-24 Daniel Chin Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
AU2002356624A1 (en) 2001-12-04 2003-06-17 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Ptp10d, tec and edtp involved in triglycerid-metabolism
US20030215899A1 (en) 2002-02-13 2003-11-20 Ceptyr, Inc. Reversible oxidation of protein tyrosine phosphatases
US20040023880A1 (en) 2002-05-03 2004-02-05 Gale Nicholas W. Methods of inducing formation of functional and organized lymphatic vessels
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
AU2005327973A1 (en) * 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
US20070134234A1 (en) 2005-09-29 2007-06-14 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
CA2633211A1 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
JP2009525282A (en) 2006-01-30 2009-07-09 （オーエスアイ）アイテツク・インコーポレーテツド Combination therapy for the treatment of angiogenic diseases
PL1994055T3 (en) * 2006-03-10 2015-02-27 Wyeth Llc Anti-5t4 antibodies and uses thereof
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
NZ571300A (en) 2006-04-07 2011-12-22 Warner Chilcott Co Llc Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CA2690244C (en) 2007-06-26 2016-08-09 Ofra Benny-Ratsaby Metap-2 inhibitor polymersomes for therapeutic administration
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2009154026A1 (en) * 2008-06-20 2009-12-23 国立大学法人岡山大学 Antibody against calcified globule and use of the same
RU2550258C2 (en) 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Binding proteins inhibiting vegf-a receptor interaction
SG172312A1 (en) 2009-01-12 2011-07-28 Akebia Therapeutics Inc Methods for treating vascular leak syndrome
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
WO2010097800A1 (en) 2009-02-26 2010-09-02 Muhammad Abdulrazik Synergistic combination of bioactive compounds for lowering of intraocular pressure
CA2756186A1 (en) * 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
DK2451279T3 (en) 2009-07-06 2019-05-20 Aerpio Therapeutics Inc Benzosulfonamide derivatives compounds thereof and their use to prevent metastases of cancer cells
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
CA2782333C (en) * 2009-12-02 2019-06-04 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
TWI510246B (en) 2010-04-30 2015-12-01 Molecular Partners Ag Modified binding proteins inhibiting the vegf-a receptor interaction
MY176514A (en) 2010-10-07 2020-08-12 Aerpio Therapeutics Inc Compositions and methods for treating ocular edema, neovascularization and related diseases
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
EP2673049A4 (en) 2011-02-11 2015-04-08 Psivida Inc Methods of treating macular edema using antiedema therapeutics
JP6400470B2 (en) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド Multispecific Fab fusion proteins and methods of use
ES2774972T3 (en) 2011-10-13 2020-07-23 Aerpio Therapeutics Inc Treatment of eye diseases
CN104039351A (en) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 Methods for treating vascular leak syndrome and cancer
RS62509B1 (en) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
SG11201503637SA (en) 2012-11-08 2015-06-29 Clearside Biomedical Inc Methods and devices for the treatment of ocular diseases in human subjects
US9440963B2 (en) 2013-03-15 2016-09-13 Aerpio Therapeutics, Inc. Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP2016522249A (en) 2013-06-20 2016-07-28 ノバルティス アーゲー Use of VEGF antagonists in the treatment of choroidal neovascularization
US20160130321A1 (en) 2013-06-20 2016-05-12 Gabriela Burian Use of a vegf antagonist in treating macular edema
CN105377891A (en) 2013-07-11 2016-03-02 诺华股份有限公司 Use of a VEGF antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
US20160159893A1 (en) 2013-07-11 2016-06-09 Gabriela Burian Use of a VEGF Antagonist in Treating Retinopathy of Prematurity
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
MX2016004736A (en) 2013-10-18 2016-07-26 Regeneron Pharma Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody.
KR102446386B1 (en) 2014-01-10 2022-09-22 아납티스바이오, 아이엔씨. Antibodies directed against interleukin-33 (il-33)
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
US9719135B2 (en) * 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
AP2017009758A0 (en) 2014-09-16 2017-02-28 Ovascience Inc Anti-vasa antibodies, and methods of production and use thereof
US20160082129A1 (en) * 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
TWI806150B (en) 2014-11-07 2023-06-21 瑞士商諾華公司 Stable protein solution formulation containing high concentration of an anti-vegf antibody
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
KR20220109488A (en) 2015-04-02 2022-08-04 몰리큘라 파트너스 아게 Recombinant binding proteins and their use
EP3341021A4 (en) 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. Anti-alk antibodies and methods for use thereof
CN108290057A (en) 2015-09-23 2018-07-17 爱尔皮奥治疗有限公司 With the method for the activators for treating intraocular pressure of TIE-2
TWI748962B (en) 2015-09-23 2021-12-11 美商建南德克公司 Optimized variants of anti-vegf antibodies
US10894823B2 (en) 2016-03-24 2021-01-19 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
US10253094B2 (en) 2016-07-20 2019-04-09 Aerpio Therapeutics, Inc. Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions

Also Published As

Publication number Publication date
JP7107914B2 (en) 2022-07-27
AU2017299581A1 (en) 2019-01-17
CA3030298A1 (en) 2018-01-25
MX2019000727A (en) 2019-05-02
JP2022101694A (en) 2022-07-06
US11180551B2 (en) 2021-11-23
WO2018017714A1 (en) 2018-01-25
SG10201912556VA (en) 2020-02-27
KR20190031246A (en) 2019-03-25
JP2020180156A (en) 2020-11-05
BR112019001206A2 (en) 2019-06-25
US20230134885A1 (en) 2023-05-04
US20200270342A1 (en) 2020-08-27
US11136389B2 (en) 2021-10-05
AU2017299581B2 (en) 2024-05-23
US10604569B2 (en) 2020-03-31
JP2019531259A (en) 2019-10-31
EP3487518A1 (en) 2019-05-29
US10597452B2 (en) 2020-03-24
US10253094B2 (en) 2019-04-09
US20200239567A1 (en) 2020-07-30
US20180022804A1 (en) 2018-01-25
EP3487518A4 (en) 2020-08-12
CN109715189A (en) 2019-05-03
US20190077863A1 (en) 2019-03-14
PH12019500145A1 (en) 2019-07-29
AU2024205789A1 (en) 2024-09-05
IL263936A (en) 2019-01-31
US20190077862A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
SG11201900464TA (en) HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201901364VA (en) Engineered target specific nucleases
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201900910TA (en) RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
SG11201909081YA (en) Anti-ilt4 antibodies and antigen-binding fragments
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201808528VA (en) Modified wound dressings
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201906200WA (en) Nucleic acid-polypeptide compositions and methods of inducing exon skipping
SG11201909011PA (en) Niraparib compositions
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201810777WA (en) Purification of multispecific antibodies
SG11201809552SA (en) Methods for breaking immunological tolerance using multiple guide rnas